Bexarotene – Uses, Dosage, Side Effects, Interactions

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 58 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Bexarotene - Uses, Dosage, Side Effects, Interactions
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Bexarotene is a retinoid analogue that is used to treat the skin manifestations of cutaneous T cell lymphoma (CTCL). Bexarotene is a retinoid, a member of benzoic acids, and a member of naphthalenes. It has a role as an antineoplastic agent. Bexarotene therapy is associated...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Bexarotene is a retinoid analogue that is used to treat the skin manifestations of cutaneous T cell lymphoma (CTCL). Bexarotene is a retinoid, a member of benzoic acids, and a member of naphthalenes. It has a role as an antineoplastic agent. Bexarotene therapy is associated with a high rate of serum enzyme elevations and rare instances of clinically apparent acute liver injury. Bexarotene is a...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Bexarotene is a retinoid analogue that is used to treat the skin manifestations of cutaneous T cell lymphoma (CTCL). Bexarotene is a retinoid, a member of benzoic acids, and a member of naphthalenes. It has a role as an antineoplastic agent. Bexarotene therapy is associated with a high rate of serum enzyme elevations and rare instances of clinically apparent acute liver injury.

Bexarotene is a synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic, and embryotoxic properties. Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)

Mechanism of Action

Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXRα, RXRβ, and RXRγ. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL. Bexarotene is a retinoid that selectively activates retinoid X receptors (RXRs), as opposed to the retinoic acid receptors, the other major target of retinoic acid (the acid form of vitamin A). By so doing it induces cell differentiation and apoptosis and prevents the development of drug resistance.[rx] It also has anti-angiogenic effects and inhibits cancer metastasis.[rx] The retinoic acid receptors (RARs) regulate cell differentiation and proliferation whereas RXRs regulate apoptosis.[rx]

Bexarotene selectively binds and activates retinoid X receptor subtypes (RXR(alpha), RXR(beta), RXR(gamma)). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptors, thyroid receptors, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models. The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.

Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biological activity distinct from that of retinoic acid receptors (RARs). Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptors, thyroid receptors, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models.

Indications

  • Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
  • Targretin capsules are indicated for the treatment of skin manifestations of advanced-stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.
  • Refractory peripheral cutaneous T-cell lymphoma
  • Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in people who are refractory to at least one prior systemic therapy (oral) and for the topical treatment of cutaneous lesions in patients with CTCL who have refractory or persistent disease after other therapies or who have not tolerated other therapies (topical)

Use in Cancer

Bexarotene is approved to treat:

Bexarotene is also being studied in the treatment of other types of cancer.

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients in the preparation(s).
  • Pregnancy and lactation
  • Women of child-bearing potential without effective birth-control measures
  • History of pancreatitis
  • Uncontrolled hypercholesterolemia
  • Uncontrolled hypertriglyceridemia
  • Hypervitaminosis A
  • Uncontrolled thyroid disease
  • Hepatic insufficiency
  • Ongoing systemic infection
  • a condition with low thyroid hormone levels
  • poor control of insulin is low or not working well. সহজ বাংলা: রক্তে চিনি বেশি থাকার রোগ।" data-rx-term="diabetes" data-rx-definition="Diabetes is a condition where blood sugar stays too high because insulin is low or not working well. সহজ বাংলা: রক্তে চিনি বেশি থাকার রোগ।">diabetes
  • high amount of triglyceride in the blood
  • low levels of white blood cells
  • alcoholism
  • clouding of the lens of the eye called cataracts
  • biliary and gallbladder problem
  • acute infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation of the pancreas
  • abnormal liver function tests
  • pregnancy
  • a patient who is producing milk and breastfeeding

Dosage

Strengths: 75 mg

Cutaneous T-cell Lymphoma

  • 300 mg/m2/day orally once a day with a meal
  • Duration of Therapy: This drug should be continued as long as the patient is a deriving benefits. In clinical trials with CTCL patients, this drug was administered for up to 118 weeks.
  • If there is no tumor response after 8 weeks of treatment and the initial dose was well-tolerated, the dose may be escalated to 400 mg/m2/day with careful monitoring.

Dose Adjustments

If Toxicity Occurs:

  • Reduce the dose to 200 mg/m2/day than to 100 mg/m2/day, or temporarily suspend treatment.
  • Carefully readjust the dose upward when toxicity is controlled.

If Fasting Triglycerides are Elevated or Become Elevated During Treatment:

  • Institute antilipemic therapy.
  • If necessary, reduce the dose to 200 mg/m2/day then to 100 mg/m2/day, or discontinue treatment.

Side Effects

The Most Common

  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • weakness
  • tiredness
  • increased sensitivity to cold
  • increase in weight
  • depression
  • joint or muscle pain
  • thin, brittle hair or fingernails
  • constipation
  • rash
  • dry skin
  • redness, scaling, or itching of the skin
  • hair loss
  • swelling of ankles, feet, and legs
  • difficulty falling asleep or staying asleep
  • nausea
  • vomiting
  • diarrhea
  • sudden or ongoing back or stomach pain
  • severe and ongoing nausea and vomiting
  • fever, sore throat, chills, or other signs of infection
  • changes in vision

More Common

  • skin reactions (mostly itchiness and rashes),
  • leucopenia,
  • headache,
  • weakness,
  • thyroid anomalies (which seem to be mediated by RXR-mediated downregulation of thyroid stimulating hormone) and
  • blood lipid anomalies such as hypercholesterolemia (high blood cholesterol) and
  • hyperlipidemia,
  • hypothyroidism.

Rare

  • blurred vision, eye pain, or seeing halos around lights;
  • low blood cell counts–fever, chills, tiredness, mouth sores, skin sores, sore throat, cough, pale skin, cold hands and feet, feeling light-headed or short of breath;
  • pancreatitis–severe pain in your upper stomach spreading to your back, nausea and vomiting; or
  • signs of underactive thyroid–extreme tiredness, dry skin, constipation, feeling more sensitive to cold temperatures, weight gain.
  • low blood cell counts;
  • headache, weakness
  • nausea, stomach pain;
  • rash, dry skin; or
  • swelling in your hands or feet.

Drug Interactions

Pregnancy and Lactation

US FDA pregnancy category: Not Assigned

Pregnancy

The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Lactation

Breastfeeding should be discontinued during treatment. Excreted into human milk: Unknown
Excreted into animal milk: Data not available

How should this medicine be used?

Bexarotene comes as a capsule to take by mouth. It is usually taken once a day with food. Take bexarotene at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take bexarotene exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole; do not chew the capsules or dissolve them in liquid or in your mouth. If you are unable to swallow the capsules whole, talk to your doctor.

Bexarotene may be harmful if it gets on the skin. Do not touch the capsules or powder from the capsules if they are broken or leaking. If the powder from a broken capsule gets on your skin, wash the area with soap and water immediately and call your doctor.

Your doctor will start you on an average dose of bexarotene and may decrease your dose if you experience side effects or increase your dose if your condition does not improve.

It may take several months or longer before you notice the full benefit of bexarotene. Do not stop taking bexarotene without talking to your doctor.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking bexarotene,

  • tell your doctor and pharmacist if you are allergic to bexarotene; or any other retinoid, such as acitretin (Soriatane), etretinate (Tegison), isotretinoin (Accutane), or tretinoin (Vesanoid); or any other medications.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Cordarone); certain antifungals such as ketoconazole (Nizoral) and itraconazole (Sporanox); cimetidine (Tagamet); clarithromycin (Biaxin); diltiazem (Cardizem); erythromycin (E.E.S., E-Mycin, Erythrocin); fluvoxamine; gemfibrozil (Lopid), HIV protease inhibitors such as indinavir (Crixivan), nelfinavir (Viracept), and ritonavir (Norvir, in Kaletra); insulin and oral medications for diabetes; nefazodone; phenobarbital; phenytoin (Dilantin); rifampin (Rifadin, Rimactane); tamoxifen (Nolvadex); verapamil (Calan); and vitamin A. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with bexarotene, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor if you drink or have ever drunk large amounts of alcohol. Also, tell your doctor if you have or have ever had pancreatitis; high levels of cholesterol and other fatty substances in the blood; diabetes; cataracts; or gall bladder, thyroid, kidney, or liver disease.
  • tell your doctor if you are breastfeeding.
  • ask your doctor about the safe use of alcoholic beverages while you are taking bexarotene. Alcohol can make the side effects of bexarotene worse.
  • plan to avoid unnecessary or prolonged exposure to sunlight and to wear protective clothing, sunglasses, and sunscreen. Bexarotene may make your skin sensitive to sunlight.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Bexarotene – Uses, Dosage, Side Effects, Interactions

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXRα, RXRβ, and RXRγ. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL. Bexarotene is a retinoid that selectively activates retinoid X receptors (RXRs), as opposed to the retinoic acid receptors, the other major target of retinoic acid (the acid form of vitamin A). By so doing it induces cell differentiation and apoptosis and prevents the development of drug resistance.[rx] It also has anti-angiogenic effects and inhibits cancer metastasis.[rx] The retinoic acid receptors (RARs) regulate cell differentiation and proliferation whereas RXRs regulate apoptosis.[rx] Bexarotene selectively binds and activates retinoid X receptor subtypes (RXR(alpha), RXR(beta), RXR(gamma)). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptors, thyroid receptors, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models. The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown. Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biological activity distinct from that of retinoic acid receptors (RARs). Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptors, thyroid receptors, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models. Indications Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies. Targretin capsules are indicated for the treatment of skin manifestations of advanced-stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment. Refractory peripheral cutaneous T-cell lymphoma Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in people who are refractory to at least one prior systemic therapy (oral) and for the topical treatment of cutaneous lesions in patients with CTCL who have refractory or persistent disease after other therapies or who have not tolerated other therapies (topical) Use in Cancer Bexarotene is approved to treat: Skin problems caused by cutaneous T-cell lymphoma that cannot be treated or that did not respond to other treatments. Bexarotene is also being studied in the treatment of other types of cancer. Contraindications Hypersensitivity to the active substance or to any of the excipients in the preparation(s). Pregnancy and lactation Women of child-bearing potential without effective birth-control measures History of pancreatitis Uncontrolled hypercholesterolemia Uncontrolled hypertriglyceridemia Hypervitaminosis A Uncontrolled thyroid disease Hepatic insufficiency Ongoing systemic infection a condition with low thyroid hormone levels poor control of diabetes high amount of triglyceride in the blood low levels of white blood cells alcoholism clouding of the lens of the eye called cataracts biliary and gallbladder problem acute inflammation of the pancreas abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: 75 mg Cutaneous T-cell Lymphoma 300 mg/m2/day orally once a day with a meal Duration of Therapy: This drug should be continued as long as the patient is a deriving benefits. In clinical trials with CTCL patients, this drug was administered for up to 118 weeks. If there is no tumor response after 8 weeks of treatment and the initial dose was well-tolerated, the dose may be escalated to 400 mg/m2/day with careful monitoring. Dose Adjustments If Toxicity Occurs: Reduce the dose to 200 mg/m2/day than to 100 mg/m2/day, or temporarily suspend treatment. Carefully readjust the dose upward when toxicity is controlled. If Fasting Triglycerides are Elevated or Become Elevated During Treatment: Institute antilipemic therapy. If necessary, reduce the dose to 200 mg/m2/day then to 100 mg/m2/day, or discontinue treatment. Side Effects The Most Common headache weakness tiredness increased sensitivity to cold increase in weight depression joint or muscle pain thin, brittle hair or fingernails constipation rash dry skin redness, scaling, or itching of the skin hair loss swelling of ankles, feet, and legs difficulty falling asleep or staying asleep nausea vomiting diarrhea sudden or ongoing back or stomach pain severe and ongoing nausea and vomiting fever, sore throat, chills, or other signs of infection changes in vision More Common skin reactions (mostly itchiness and rashes), leucopenia, headache, weakness, thyroid anomalies (which seem to be mediated by RXR-mediated downregulation of thyroid stimulating hormone) and blood lipid anomalies such as hypercholesterolemia (high blood cholesterol) and hyperlipidemia, hypothyroidism. Rare blurred vision, eye pain, or seeing halos around lights; low blood cell counts--fever, chills, tiredness, mouth sores, skin sores, sore throat, cough, pale skin, cold hands and feet, feeling light-headed or short of breath; pancreatitis--severe pain in your upper stomach spreading to your back, nausea and vomiting; or signs of underactive thyroid--extreme tiredness, dry skin, constipation, feeling more sensitive to cold temperatures, weight gain. low blood cell counts; headache, weakness nausea, stomach pain; rash, dry skin; or swelling in your hands or feet. Drug Interactions DRUG INTERACTION Abametapir The serum concentration of Bexarotene can be increased when it is combined with Abametapir. Abatacept The metabolism of Bexarotene can be increased when combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Bexarotene. Abemaciclib The metabolism of Abemaciclib can be increased when combined with Bexarotene. Abrocitinib The metabolism of Abrocitinib can be decreased when combined with Bexarotene. Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Bexarotene. Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Bexarotene. Acetohexamide The metabolism of Acetohexamide can be decreased when combined with Bexarotene. Acetyl sulfisoxazole The metabolism of Bexarotene can be decreased when combined with Acetyl sulfisoxazole. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bexarotene. Adalimumab The metabolism of Bexarotene can be increased when combined with Adalimumab. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Bexarotene. Agomelatine The metabolism of Bexarotene can be decreased when combined with Agomelatine. Albendazole The metabolism of Albendazole can be increased when combined with Bexarotene. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bexarotene. Alectinib The metabolism of Alectinib can be increased when combined with Bexarotene. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Bexarotene. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bexarotene. thymus tissue The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Bexarotene. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Bexarotene. Almotriptan The metabolism of Almotriptan can be decreased when combined with Bexarotene. Alosetron The metabolism of Alosetron can be decreased when combined with Bexarotene. Alpelisib The serum concentration of Bexarotene can be decreased when it is combined with Alpelisib. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Bexarotene. Altretamine The risk or severity of adverse effects can be increased when Bexarotene is combined with Altretamine. Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Bexarotene. Aminophylline The metabolism of Aminophylline can be increased when combined with Bexarotene. Amiodarone The metabolism of Bexarotene can be decreased when combined with Amiodarone. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Bexarotene. Amodiaquine The metabolism of Amodiaquine can be decreased when combined with Bexarotene. Amprenavir The metabolism of Bexarotene can be decreased when combined with Amprenavir. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Bexarotene. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Bexarotene. Anakinra The metabolism of Bexarotene can be increased when combined with Anakinra. Anastrozole The metabolism of Anastrozole can be decreased when combined with Bexarotene. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Bexarotene. Anifrolumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Bexarotene. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bexarotene. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Bexarotene. Antilymphocyte The risk or severity of adverse effects can be increased when Bexarotene is combined with Antilymphocyte immunoglobulin (horse). Antipyrine The metabolism of Antipyrine can be decreased when combined with Bexarotene. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Bexarotene. Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Bexarotene. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bexarotene. Apalutamide The metabolism of Bexarotene can be increased when combined with Apalutamide. Apixaban The metabolism of Apixaban can be decreased when combined with Bexarotene. Apomorphine The metabolism of Apomorphine can be decreased when combined with Bexarotene. Apremilast The metabolism of Bexarotene can be increased when combined with Apremilast. Aprepitant The metabolism of Bexarotene can be decreased when combined with Aprepitant. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Bexarotene. Arformoterol The metabolism of Arformoterol can be decreased when combined with Bexarotene. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Bexarotene. Aripiprazole The metabolism of Aripiprazole can be increased when combined with Bexarotene. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Bexarotene. Armodafinil The metabolism of Bexarotene can be decreased when combined with Armodafinil. Arsenic trioxide The risk or severity of adverse effects can be increased when Bexarotene is combined with Arsenic trioxide. Artemether The metabolism of Artemether can be decreased when combined with Bexarotene. Articaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Articaine. Asciminib The metabolism of Bexarotene can be decreased when combined with Asciminib. Astemizole The metabolism of Astemizole can be increased when combined with Bexarotene. AstraZeneca COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Bexarotene. Asunaprevir The metabolism of Asunaprevir can be decreased when combined with Bexarotene. Atazanavir The metabolism of Bexarotene can be decreased when combined with Atazanavir. Atogepant The serum concentration of Atogepant can be decreased when it is combined with Bexarotene. Atorvastatin The serum concentration of Atorvastatin can be decreased when it is combined with Bexarotene. Atovaquone The metabolism of Bexarotene can be decreased when combined with Atovaquone. Avanafil The serum concentration of Avanafil can be increased when it is combined with Bexarotene. Avapritinib The metabolism of Bexarotene can be decreased when combined with Avapritinib. Avatrombopag The metabolism of Bexarotene can be increased when combined with Avatrombopag. Axitinib The metabolism of Axitinib can be increased when combined with Bexarotene. Azacitidine The risk or severity of adverse effects can be increased when Bexarotene is combined with Azacitidine. Azathioprine The risk or severity of adverse effects can be increased when Bexarotene is combined with Azathioprine. Azelastine The metabolism of Azelastine can be decreased when combined with Bexarotene. Azithromycin The metabolism of Azithromycin can be increased when combined with Bexarotene. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Bexarotene. Bacillus calmette-guerin The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Bexarotene. Bacillus antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Bexarotene. Baricitinib The risk or severity of adverse effects can be increased when Bexarotene is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Bexarotene. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Bexarotene. Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Bexarotene is combined with Beclomethasone dipropionate. Belatacept The risk or severity of adverse effects can be increased when Bexarotene is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Bexarotene is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Bexarotene is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Bexarotene. Bendamustine The risk or severity of adverse effects can be increased when Bexarotene is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bexarotene. Benzocaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Bexarotene. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Benzyl alcohol. Berotralstat The metabolism of Bexarotene can be decreased when combined with Berotralstat. Betamethasone The risk or severity of adverse effects can be increased when Bexarotene is combined with Betamethasone. Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Bexarotene. Bicalutamide The metabolism of Bicalutamide can be increased when combined with Bexarotene. Bimekizumab The metabolism of Bexarotene can be increased when combined with Bimekizumab. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Bexarotene. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Bexarotene. Blinatumomab The risk or severity of adverse effects can be increased when Bexarotene is combined with Blinatumomab. Bortezomib The metabolism of Bortezomib can be increased when combined with Bexarotene. Bosentan The metabolism of Bexarotene can be increased when combined with Bosentan. Bosutinib The metabolism of Bosutinib can be increased when combined with Bexarotene. Brentuximab vedotin The metabolism of Brentuximab vedotin can be increased when combined with Bexarotene. Brigatinib The metabolism of Brigatinib can be increased when combined with Bexarotene. Brivaracetam The metabolism of Brivaracetam can be decreased when combined with Bexarotene. Brodalumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Brodalumab. Budesonide The risk or severity of adverse effects can be increased when Bexarotene is combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Bupivacaine. Buprenorphine The metabolism of Buprenorphine can be decreased when combined with Bexarotene. Bupropion The metabolism of Bupropion can be decreased when combined with Bexarotene. Busulfan The metabolism of Busulfan can be increased when combined with Bexarotene. Butacaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Butamben. Cabazitaxel The metabolism of Cabazitaxel can be increased when combined with Bexarotene. Cabergoline The metabolism of Cabergoline can be increased when combined with Bexarotene. Cabozantinib The metabolism of Cabozantinib can be decreased when combined with Bexarotene. Canakinumab The metabolism of Bexarotene can be increased when combined with Canakinumab. Candesartan cilexetil The metabolism of Candesartan cilexetil can be decreased when combined with Bexarotene. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Bexarotene. Cannabidiol The metabolism of Bexarotene can be decreased when combined with Cannabidiol. Capecitabine The risk or severity of adverse effects can be increased when Bexarotene is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Bexarotene. Capmatinib The serum concentration of Capmatinib can be decreased when it is combined with Bexarotene. Capsaicin The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Capsaicin. Carbamazepine The metabolism of Carbamazepine can be increased when combined with Bexarotene. Carboplatin The serum concentration of Bexarotene can be increased when it is combined with Carboplatin. Carfilzomib The risk or severity of adverse effects can be increased when Bexarotene is combined with Carfilzomib. Cariprazine The metabolism of Cariprazine can be increased when combined with Bexarotene. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Bexarotene. Carvedilol The metabolism of Carvedilol can be decreased when combined with Bexarotene. Celecoxib The metabolism of Celecoxib can be decreased when combined with Bexarotene. Cenobamate The serum concentration of Bexarotene can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Cephalexin can be increased when combined with Bexarotene. Ceritinib The metabolism of Ceritinib can be increased when combined with Bexarotene. Cerivastatin The metabolism of Cerivastatin can be decreased when combined with Bexarotene. Certolizumab pegol The metabolism of Bexarotene can be increased when combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Bexarotene. Chloramphenicol The risk or severity of adverse effects can be increased when Bexarotene is combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Chloroprocaine. Chloroquine The metabolism of Chloroquine can be decreased when combined with Bexarotene. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Bexarotene. Chlorpromazine The metabolism of Chlorpromazine can be increased when combined with Bexarotene. Chlorpropamide The metabolism of Chlorpropamide can be decreased when combined with Bexarotene. Ciclesonide The risk or severity of adverse effects can be increased when Bexarotene is combined with Ciclesonide. Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Bexarotene. Cimetidine The metabolism of Bexarotene can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Cinchocaine. Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Bexarotene. Ciprofloxacin The metabolism of Bexarotene can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Cisapride can be increased when combined with Bexarotene. Cisplatin The risk or severity of adverse effects can be increased when Bexarotene is combined with Cisplatin. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Bexarotene. Clarithromycin The metabolism of Bexarotene can be decreased when combined with Clarithromycin. Clevidipine The metabolism of Bexarotene can be decreased when combined with Clevidipine. Clindamycin The metabolism of Clindamycin can be increased when combined with Bexarotene. Clobetasol propionate The risk or severity of adverse effects can be increased when Bexarotene is combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Bexarotene is combined with Clofarabine. Clomipramine The metabolism of Clomipramine can be increased when combined with Bexarotene. Clonazepam The metabolism of Clonazepam can be increased when combined with Bexarotene. Clonidine The metabolism of Clonidine can be increased when combined with Bexarotene. Clopidogrel The metabolism of Bexarotene can be decreased when combined with Clopidogrel. Clostridium tetani The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bexarotene. Clozapine The risk or severity of neutropenia can be increased when Bexarotene is combined with Clozapine. Cobicistat The metabolism of Bexarotene can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Cobimetinib can be increased when combined with Bexarotene. Cocaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Cocaine. Conivaptan The metabolism of Bexarotene can be decreased when combined with Conivaptan. Copanlisib The metabolism of Copanlisib can be increased when combined with Bexarotene. Corticotropin The risk or severity of adverse effects can be increased when Bexarotene is combined with Corticotropin. Cortisone acetate The risk or severity of adverse effects can be increased when Bexarotene is combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bexarotene. Crizotinib The metabolism of Crizotinib can be increased when combined with Bexarotene. Curcumin The metabolism of Bexarotene can be decreased when combined with Curcumin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bexarotene. Cyclizine The metabolism of Bexarotene can be decreased when combined with Cyclizine. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Bexarotene. Cyclophosphamide The metabolism of Cyclophosphamide can be increased when combined with Bexarotene. Cyclosporine Bexarotene may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Bexarotene. Cyproterone acetate The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Bexarotene. Cytarabine The risk or severity of adverse effects can be increased when Bexarotene is combined with Cytarabine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Bexarotene. Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Bexarotene. Dabrafenib The serum concentration of Bexarotene can be decreased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Bexarotene is combined with Dacarbazine. Daclatasvir The metabolism of Daclatasvir can be increased when combined with Bexarotene. Dacomitinib The metabolism of Dacomitinib can be increased when combined with Bexarotene. Dactinomycin The risk or severity of adverse effects can be increased when Bexarotene is combined with Dactinomycin. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Bexarotene. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Bexarotene. Danazol The metabolism of Bexarotene can be decreased when combined with Danazol. Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Bexarotene. Dapsone The metabolism of Dapsone can be decreased when combined with Bexarotene. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bexarotene. Daridorexant The metabolism of Daridorexant can be increased when combined with Bexarotene. Darolutamide The serum concentration of Darolutamide can be decreased when it is combined with Bexarotene. Darunavir The metabolism of Bexarotene can be decreased when combined with Darunavir. Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Bexarotene. Dasatinib The metabolism of Dasatinib can be increased when combined with Bexarotene. Daunorubicin The risk or severity of adverse effects can be increased when Bexarotene is combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Bexarotene is combined with Decitabine. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Bexarotene. Deflazacort The serum concentration of Deflazacort can be decreased when it is combined with Bexarotene. Delafloxacin The metabolism of Bexarotene can be increased when combined with Delafloxacin. Delavirdine The metabolism of Bexarotene can be decreased when combined with Delavirdine. Demeclocycline The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Demeclocycline. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Bexarotene. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Bexarotene. Desogestrel The therapeutic efficacy of Desogestrel can be decreased when used in combination with Bexarotene. Desoximetasone The risk or severity of adverse effects can be increased when Bexarotene is combined with Desoximetasone. Desvenlafaxine The metabolism of Bexarotene can be decreased when combined with Desvenlafaxine. Deucravacitinib The risk or severity of adverse effects can be increased when Bexarotene is combined with Deucravacitinib. Dexamethasone The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexamethasone. Dexibuprofen The metabolism of Dexibuprofen can be decreased when combined with Bexarotene. Dexrazoxane The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexrazoxane. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Bexarotene. Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Bexarotene. Diacerein The metabolism of Bexarotene can be decreased when combined with Diacerein. Diazepam The metabolism of Diazepam can be decreased when combined with Bexarotene. Diclofenac The metabolism of Diclofenac can be decreased when combined with Bexarotene. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Bexarotene. Dienogest The therapeutic efficacy of Dienogest can be decreased when used in combination with Bexarotene. Diethylstilbestrol The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Bexarotene. Difluocortolone The risk or severity of adverse effects can be increased when Bexarotene is combined with Difluocortolone. Digitoxin The metabolism of Digitoxin can be increased when combined with Bexarotene. Dihydroergocornine The metabolism of Dihydroergocornine can be increased when combined with Bexarotene. Dihydroergocristine The metabolism of Dihydroergocristine can be increased when combined with Bexarotene. Dihydroergotamine The metabolism of Dihydroergotamine can be increased when combined with Bexarotene. Diltiazem The metabolism of Bexarotene can be decreased when combined with Diltiazem. Dimethyl fumarate The risk or severity of adverse effects can be increased when Bexarotene is combined with Dimethyl fumarate. Dinutuximab The risk or severity of adverse effects can be increased when Bexarotene is combined with Dinutuximab. Diosmin The metabolism of Bexarotene can be decreased when combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Bexarotene. Diroximel fumarate The risk or severity of adverse effects can be increased when Bexarotene is combined with Diroximel fumarate. Docetaxel The metabolism of Docetaxel can be increased when combined with Bexarotene. Doconexent The metabolism of Bexarotene can be decreased when combined with Doconexent. Dofetilide The metabolism of Dofetilide can be increased when combined with Bexarotene. Domperidone The metabolism of Domperidone can be decreased when combined with Bexarotene. Donepezil The metabolism of Donepezil can be decreased when combined with Bexarotene. Doxazosin The metabolism of Doxazosin can be increased when combined with Bexarotene. Doxepin The metabolism of Doxepin can be decreased when combined with Bexarotene. Doxorubicin The metabolism of Doxorubicin can be increased when combined with Bexarotene. Doxycycline The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Doxycycline. Dronabinol The metabolism of Bexarotene can be decreased when combined with Dronabinol. Dronedarone The metabolism of Dronedarone can be increased when combined with Bexarotene. Drospirenone The therapeutic efficacy of Drospirenone can be decreased when used in combination with Bexarotene. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bexarotene. Duloxetine The metabolism of Duloxetine can be decreased when combined with Bexarotene. Duvelisib The metabolism of Duvelisib can be increased when combined with Bexarotene. Dyclonine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Dyclonine. Ebastine The metabolism of Ebastine can be increased when combined with Bexarotene. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Bexarotene. Eculizumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Bexarotene. Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Bexarotene. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Bexarotene. Efavirenz The metabolism of Bexarotene can be decreased when combined with Efavirenz. Elagolix The metabolism of Elagolix can be decreased when combined with Bexarotene. Eletriptan The metabolism of Bexarotene can be decreased when combined with Eletriptan. Elexacaftor The metabolism of Elexacaftor can be increased when combined with Bexarotene. Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Bexarotene. Elvitegravir The metabolism of Bexarotene can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Bexarotene can be increased when combined with Emapalumab. Enasidenib The metabolism of Enasidenib can be increased when combined with Bexarotene. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Bexarotene. Entrectinib The metabolism of Entrectinib can be increased when combined with Bexarotene. Enzalutamide The serum concentration of Bexarotene can be decreased when it is combined with Enzalutamide. Epinephrine The metabolism of Bexarotene can be decreased when combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Bexarotene is combined with Epirubicin. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Bexarotene. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Bexarotene. Eravacycline The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Eravacycline. Erdafitinib The metabolism of Erdafitinib can be increased when combined with Bexarotene. Ergotamine The metabolism of Bexarotene can be decreased when combined with Ergotamine. Eribulin The risk or severity of adverse effects can be increased when Bexarotene is combined with Eribulin. Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Bexarotene. Erythromycin The metabolism of Bexarotene can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bexarotene. Esketamine The metabolism of Esketamine can be decreased when combined with Bexarotene. Estetrol The therapeutic efficacy of Estetrol can be decreased when used in combination with Bexarotene. Estradiol The therapeutic efficacy of Estradiol can be decreased when used in combination with Bexarotene. Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Bexarotene. Estradiol benzoate The metabolism of Estradiol benzoate can be increased when combined with Bexarotene. Estradiol cypionate The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Bexarotene. Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Bexarotene. Estradiol valerate The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Bexarotene. Estramustine The risk or severity of adverse effects can be increased when Bexarotene is combined with Estramustine. Estrone sulfate The metabolism of Estrone sulfate can be increased when combined with Bexarotene. Eszopiclone The serum concentration of Eszopiclone can be decreased when it is combined with Bexarotene. Etanercept The metabolism of Bexarotene can be increased when combined with Etanercept. Ethambutol The metabolism of Bexarotene can be decreased when combined with Ethambutol. Ethanol The metabolism of Bexarotene can be decreased when combined with Ethanol. Ethinylestradiol The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Bexarotene. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Ethyl chloride. Ethynodiol diacetate The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Bexarotene. Etidocaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Etidocaine. Etodolac The metabolism of Etodolac can be decreased when combined with Bexarotene. Etonogestrel The metabolism of Etonogestrel can be increased when combined with Bexarotene. Etoposide The metabolism of Etoposide can be increased when combined with Bexarotene. Etoricoxib The metabolism of Bexarotene can be decreased when combined with Etoricoxib. Etravirine The metabolism of Bexarotene can be decreased when combined with Etravirine. Everolimus The metabolism of Everolimus can be increased when combined with Bexarotene. Felbamate The metabolism of Bexarotene can be decreased when combined with Felbamate. Felodipine The metabolism of Bexarotene can be decreased when combined with Felodipine. Fenofibrate The metabolism of Fenofibrate can be increased when combined with Bexarotene. Filgotinib The risk or severity of adverse effects can be increased when Bexarotene is combined with Filgotinib. Finerenone The therapeutic efficacy of Finerenone can be decreased when used in combination with Bexarotene. Fingolimod Bexarotene may increase the immunosuppressive activities of Fingolimod. Flecainide The metabolism of Bexarotene can be decreased when combined with Flecainide. Floxuridine The risk or severity of adverse effects can be increased when Bexarotene is combined with Floxuridine. Fluconazole The metabolism of Bexarotene can be decreased when combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Bexarotene is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Bexarotene is combined with Fludarabine. Fludrocortisone The risk or severity of adverse effects can be increased when Bexarotene is combined with Fludrocortisone. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Bexarotene. Flunarizine The metabolism of Flunarizine can be decreased when combined with Bexarotene. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Bexarotene. Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Bexarotene. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocinolone acetonide. Fluocinonide The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocinonide. Fluocortolone The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluorometholone. Fluorouracil The metabolism of Fluorouracil can be decreased when combined with Bexarotene. Fluoxetine The metabolism of Bexarotene can be decreased when combined with Fluoxetine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bexarotene. Fluprednisolone The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluprednisolone. Flurbiprofen The metabolism of Flurbiprofen can be decreased when combined with Bexarotene. Fluticasone The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluticasone furoate. Fluticasone propionate The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluticasone propionate. Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Bexarotene. Fluvoxamine The metabolism of Bexarotene can be decreased when combined with Fluvoxamine. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Bexarotene. Formoterol The metabolism of Formoterol can be decreased when combined with Bexarotene. Fosaprepitant The metabolism of Fosaprepitant can be increased when combined with Bexarotene. Fosnetupitant The metabolism of Bexarotene can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Fosphenytoin can be increased when combined with Bexarotene. Fusidic acid The metabolism of Bexarotene can be decreased when combined with Fusidic acid. Gallium nitrate The risk or severity of adverse effects can be increased when Bexarotene is combined with Gallium nitrate. Ganaxolone The metabolism of Ganaxolone can be increased when combined with Bexarotene. Gemcitabine The risk or severity of adverse effects can be increased when Bexarotene is combined with Gemcitabine. Gemfibrozil The metabolism of Bexarotene can be decreased when combined with Gemfibrozil. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bexarotene. Gestrinone The therapeutic efficacy of Gestrinone can be decreased when used in combination with Bexarotene. Gilteritinib The metabolism of Gilteritinib can be increased when combined with Bexarotene. Ginkgo biloba The metabolism of Bexarotene can be decreased when combined with Ginkgo biloba. Glasdegib The metabolism of Glasdegib can be decreased when combined with Bexarotene. Glatiramer The risk or severity of adverse effects can be increased when Bexarotene is combined with Glatiramer. Gliclazide The metabolism of Gliclazide can be decreased when combined with Bexarotene. Glimepiride The metabolism of Bexarotene can be decreased when combined with Glimepiride. Glipizide The metabolism of Glipizide can be decreased when combined with Bexarotene. Gliquidone The metabolism of Gliquidone can be decreased when combined with Bexarotene. Glyburide The metabolism of Bexarotene can be decreased when combined with Glyburide. Golimumab The metabolism of Bexarotene can be increased when combined with Golimumab. Guselkumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Guselkumab. Irbesartan The metabolism of Irbesartan can be decreased when combined with Bexarotene. Irinotecan The metabolism of Irinotecan can be increased when combined with Bexarotene. Isavuconazole The metabolism of Isavuconazole can be increased when combined with Bexarotene. Isavuconazonium The metabolism of Bexarotene can be decreased when combined with Isavuconazonium. Isoniazid The metabolism of Bexarotene can be decreased when combined with Isoniazid. Isradipine The metabolism of Bexarotene can be decreased when combined with Isradipine. Istradefylline The metabolism of Istradefylline can be decreased when combined with Bexarotene. Itraconazole The metabolism of Bexarotene can be decreased when combined with Itraconazole. Ivosidenib The metabolism of Bexarotene can be increased when combined with Ivosidenib. Ixabepilone The metabolism of Ixabepilone can be increased when combined with Bexarotene. Ixazomib The metabolism of Ixazomib can be increased when combined with Bexarotene. Ixekizumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Ixekizumab. COVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Bexarotene. Japanese encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Bexarotene. Ketamine The metabolism of Ketamine can be decreased when combined with Bexarotene. Ketoconazole The metabolism of Bexarotene can be decreased when combined with Ketoconazole. Ketorolac The metabolism of Ketorolac can be decreased when combined with Bexarotene. Lacosamide The metabolism of Lacosamide can be increased when combined with Bexarotene. Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Bexarotene. Lapatinib The metabolism of Lapatinib can be decreased when combined with Bexarotene. Lefamulin The metabolism of Lefamulin can be increased when combined with Bexarotene. Leflunomide The risk or severity of adverse effects can be increased when Bexarotene is combined with Leflunomide. Lemborexant The serum concentration of Lemborexant can be decreased when it is combined with Bexarotene. Lenalidomide The risk or severity of adverse effects can be increased when Bexarotene is combined with Lenalidomide. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Bexarotene. Lesinurad The metabolism of Lesinurad can be decreased when combined with Bexarotene. Levacetylmethadol The metabolism of Levacetylmethadol can be increased when combined with Bexarotene. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Levobupivacaine. Levoketoconazole The metabolism of Bexarotene can be decreased when combined with Levoketoconazole. Levomilnacipran The metabolism of Levomilnacipran can be increased when combined with Bexarotene. Levonorgestrel The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Bexarotene. Lidocaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Lidocaine. Linagliptin The metabolism of Linagliptin can be increased when combined with Bexarotene. Linezolid The risk or severity of adverse effects can be increased when Bexarotene is combined with Linezolid. Lipegfilgrastim Bexarotene may increase the myelosuppressive activities of Lipegfilgrastim. Lomitapide The metabolism of Lomitapide can be increased when combined with Bexarotene. Lomustine The risk or severity of adverse effects can be increased when Bexarotene is combined with Lomustine. Lonafarnib The metabolism of Bexarotene can be decreased when combined with Lonafarnib. Loperamide The metabolism of Loperamide can be decreased when combined with Bexarotene. Lopinavir The serum concentration of Bexarotene can be increased when it is combined with Lopinavir. Lornoxicam The metabolism of Lornoxicam can be decreased when combined with Bexarotene. Losartan The metabolism of Losartan can be decreased when combined with Bexarotene. Lovastatin The metabolism of Bexarotene can be decreased when combined with Lovastatin. Lumacaftor The metabolism of Bexarotene can be increased when combined with Lumacaftor. Lumateperone The serum concentration of Lumateperone can be decreased when it is combined with Bexarotene. Lumiracoxib The metabolism of Lumiracoxib can be decreased when combined with Bexarotene. Lurbinectedin The serum concentration of Lurbinectedin can be decreased when it is combined with Bexarotene. Lymecycline The risk or severity of pseudotumor cerebri can be increased when Lymecycline is combined with Bexarotene. Lynestrenol The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Bexarotene. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Bexarotene. Manidipine The metabolism of Bexarotene can be decreased when combined with Manidipine. Mavacamten The serum concentration of Bexarotene can be decreased when it is combined with Mavacamten. Measles virus vaccine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Bexarotene. Mechlorethamine The risk or severity of adverse effects can be increased when Bexarotene is combined with Mechlorethamine. Medroxyprogesterone The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Bexarotene. Mefenamic acid The metabolism of Mefenamic acid can be decreased when combined with Bexarotene. Megestrol acetate The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Bexarotene. Meloxicam The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Bexarotene is combined with Melphalan. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Bexarotene. Meperidine The metabolism of Meperidine can be increased when combined with Bexarotene. Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Bexarotene. Mepivacaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Mepolizumab. Meprednisone The risk or severity of adverse effects can be increased when Bexarotene is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Bexarotene is combined with Mercaptopurine. Mestranol The therapeutic efficacy of Mestranol can be decreased when used in combination with Bexarotene. Metacycline The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Metacycline. Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Bexarotene. Methadone The metabolism of Methadone can be decreased when combined with Bexarotene. Methimazole The metabolism of Bexarotene can be decreased when combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Bexarotene. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bexarotene. Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Bexarotene. Methylene blue The metabolism of Bexarotene can be decreased when combined with Methylene blue. Methylprednisolone The risk or severity of adverse effects can be increased when Bexarotene is combined with Methylprednisolone. Methylprednisone The metabolism of Methylprednisone can be increased when combined with Bexarotene. Methysergide The metabolism of Methysergide can be increased when combined with Bexarotene. Metreleptin The metabolism of Bexarotene can be increased when combined with Metreleptin. Metronidazole The metabolism of Bexarotene can be decreased when combined with Metronidazole. Miconazole The metabolism of Bexarotene can be decreased when combined with Miconazole. Midostaurin The metabolism of Bexarotene can be decreased when combined with Midostaurin. Mifepristone The metabolism of Mifepristone can be increased when combined with Bexarotene. Milnacipran The metabolism of Milnacipran can be increased when combined with Bexarotene. Minocycline The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Minocycline. Mitapivat The metabolism of Mitapivat can be increased when combined with Bexarotene. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Bexarotene. Mitotane The metabolism of Bexarotene can be increased when combined with Mitotane. Mitoxantrone The risk or severity of adverse effects can be increased when Bexarotene is combined with Mitoxantrone. Montelukast The metabolism of Montelukast can be decreased when combined with Bexarotene. Morphine The metabolism of Morphine can be decreased when combined with Bexarotene. Mosunetuzumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Mosunetuzumab. Mumps virus strain The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Bexarotene. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Bexarotene. Mycophenolate The risk or severity of adverse effects can be increased when Bexarotene is combined with Mycophenolate mofetil. Mycophenolic acid The risk or severity of adverse effects can be increased when Bexarotene is combined with Mycophenolic acid. Nabilone The metabolism of Nabilone can be decreased when combined with Bexarotene. Nabumetone The metabolism of Nabumetone can be decreased when combined with Bexarotene. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Bexarotene. Naloxone The metabolism of Bexarotene can be decreased when combined with Naloxone. Naproxen The metabolism of Naproxen can be decreased when combined with Bexarotene. Natalizumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Natalizumab. Nateglinide The metabolism of Nateglinide can be decreased when combined with Bexarotene. Nefazodone The metabolism of Bexarotene can be decreased when combined with Nefazodone. Nelarabine The risk or severity of adverse effects can be increased when Bexarotene is combined with Nelarabine. Nelfinavir The metabolism of Bexarotene can be decreased when combined with Nelfinavir. Neratinib The metabolism of Neratinib can be increased when combined with Bexarotene. Netupitant The metabolism of Netupitant can be increased when combined with Bexarotene. Nevirapine The metabolism of Bexarotene can be decreased when combined with Nevirapine. Nicardipine The metabolism of Bexarotene can be decreased when combined with Nicardipine. Niclosamide The metabolism of Niclosamide can be decreased when combined with Bexarotene. Nilotinib The metabolism of Bexarotene can be decreased when combined with Nilotinib. Nilutamide The metabolism of Bexarotene can be decreased when combined with Nilutamide. Nilvadipine The metabolism of Bexarotene can be decreased when combined with Nilvadipine. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Bexarotene. Nintedanib The metabolism of Nintedanib can be increased when combined with Bexarotene. Nomegestrol The metabolism of Nomegestrol can be increased when combined with Bexarotene. Nomegestrol acetate The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Bexarotene. Norelgestromin The metabolism of Norelgestromin can be increased when combined with Bexarotene. Norethisterone The therapeutic efficacy of Norethisterone can be decreased when used in combination with Bexarotene. Norethynodrel The therapeutic efficacy of Norethynodrel can be decreased when used in combination with Bexarotene. Norgestimate The therapeutic efficacy of Norgestimate can be decreased when used in combination with Bexarotene. Norgestrel The therapeutic efficacy of Norgestrel can be decreased when used in combination with Bexarotene. Nortriptyline The metabolism of Nortriptyline can be increased when combined with Bexarotene. Noscapine The metabolism of Bexarotene can be decreased when combined with Noscapine. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Bexarotene. Obinutuzumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Obinutuzumab. Ocrelizumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Ocrelizumab. Ofatumumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Ofatumumab. Olanzapine The metabolism of Bexarotene can be decreased when combined with Olanzapine. Olaparib The metabolism of Olaparib can be increased when combined with Bexarotene. Oliceridine The serum concentration of Oliceridine can be decreased when it is combined with Bexarotene. Olodaterol The metabolism of Olodaterol can be decreased when combined with Bexarotene. Omadacycline The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Omadacycline. Ombitasvir The metabolism of Ombitasvir can be decreased when combined with Bexarotene. Omeprazole The metabolism of Omeprazole can be decreased when combined with Bexarotene. Ondansetron The metabolism of Ondansetron can be decreased when combined with Bexarotene. Oritavancin The metabolism of Bexarotene can be decreased when combined with Oritavancin. Osimertinib The metabolism of Osimertinib can be increased when combined with Bexarotene. Ospemifene The metabolism of Ospemifene can be decreased when combined with Bexarotene. Oxaliplatin The risk or severity of adverse effects can be increased when Bexarotene is combined with Oxaliplatin. Oxandrolone The metabolism of Bexarotene can be decreased when combined with Oxandrolone. Oxetacaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Oxybuprocaine. Oxytetracycline The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Oxytetracycline. Ozanimod The risk or severity of adverse effects can be increased when Bexarotene is combined with Ozanimod. Paclitaxel The serum concentration of Bexarotene can be increased when it is combined with Paclitaxel. Pacritinib The serum concentration of Pacritinib can be decreased when it is combined with Bexarotene. Palbociclib The metabolism of Palbociclib can be increased when combined with Bexarotene. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Bexarotene. Palovarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Palovarotene. Panobinostat The metabolism of Panobinostat can be increased when combined with Bexarotene. Paramethadione The metabolism of Paramethadione can be decreased when combined with Bexarotene. Parecoxib The metabolism of Parecoxib can be decreased when combined with Bexarotene. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Bexarotene. Paroxetine The metabolism of Bexarotene can be decreased when combined with Paroxetine. Pazopanib The metabolism of Pazopanib can be increased when combined with Bexarotene. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bexarotene. Pegcetacoplan The risk or severity of adverse effects can be increased when Bexarotene is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bexarotene. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bexarotene. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bexarotene. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Bexarotene is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Bexarotene is combined with Pemetrexed. Pemigatinib The metabolism of Pemigatinib can be increased when combined with Bexarotene. Penicillamine The risk or severity of adverse effects can be increased when Bexarotene is combined with Penicillamine. Pentobarbital The metabolism of Bexarotene can be increased when combined with Pentobarbital. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Bexarotene. Pentostatin The risk or severity of adverse effects can be increased when Bexarotene is combined with Pentostatin. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Bexarotene. Perampanel The metabolism of Perampanel can be increased when combined with Bexarotene. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bexarotene. Pexidartinib The metabolism of Pexidartinib can be increased when combined with Bexarotene. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Bexarotene. Phenobarbital The metabolism of Bexarotene can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Phenol. Phenprocoumon The metabolism of Phenprocoumon can be increased when combined with Bexarotene. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bexarotene. Phenylbutazone The metabolism of Bexarotene can be decreased when combined with Phenylbutazone. Phenytoin The metabolism of Phenytoin can be decreased when combined with Bexarotene. Pimavanserin The metabolism of Pimavanserin can be increased when combined with Bexarotene. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bexarotene. Pimozide The metabolism of Pimozide can be increased when combined with Bexarotene. Pioglitazone The metabolism of Pioglitazone can be decreased when combined with Bexarotene Piroxicam The metabolism of Piroxicam can be decreased when combined with Bexarotene. Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Bexarotene. Pitolisant The serum concentration of Bexarotene can be decreased when it is combined with Pitolisant. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Bexarotene. Pomalidomide The metabolism of Pomalidomide can be increased when combined with Bexarotene. Ponatinib The metabolism of Ponatinib can be increased when combined with Bexarotene. Ponesimod The risk or severity of adverse effects can be increased when Bexarotene is combined with Ponesimod. Posaconazole The metabolism of Bexarotene can be decreased when combined with Posaconazole. Pralatrexate The risk or severity of adverse effects can be increased when Bexarotene is combined with Pralatrexate. Pralsetinib The metabolism of Bexarotene can be decreased when combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Bexarotene. Prednisolone The risk or severity of adverse effects can be increased when Bexarotene is combined with Prednisolone. Prednisone The risk or severity of adverse effects can be increased when Bexarotene is combined with Prednisone. Pretomanid The metabolism of Pretomanid can be increased when combined with Bexarotene. Prilocaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Prilocaine. Primaquine The metabolism of Bexarotene can be decreased when combined with Primaquine. Primidone The metabolism of Bexarotene can be increased when combined with Primidone. Probenecid The metabolism of Bexarotene can be decreased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Bexarotene is combined with Procarbazine. Progesterone The metabolism of Progesterone can be increased when combined with Bexarotene. Proguanil The metabolism of Proguanil can be decreased when combined with Bexarotene. Promazine The metabolism of Promazine can be decreased when combined with Bexarotene. Promethazine The metabolism of Bexarotene can be decreased when combined with Promethazine. Proparacaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Proparacaine. Propofol The metabolism of Propofol can be decreased when combined with Bexarotene. Propoxycaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Propoxycaine. Propylthiouracil The risk or severity of adverse effects can be increased when Bexarotene is combined with Propylthiouracil. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Bexarotene. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Bexarotene. Quazepam The metabolism of Quazepam can be decreased when combined with Bexarotene. Quinidine The metabolism of Quinidine can be increased when combined with Bexarotene. Quinine The metabolism of Quinine can be decreased when combined with Bexarotene. immune globulin The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Bexarotene. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bexarotene. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Bexarotene. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Bexarotene. Ramelteon The metabolism of Ramelteon can be decreased when combined with Bexarotene. Ranolazine The metabolism of Ranolazine can be increased when combined with Bexarotene. Ravulizumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Ravulizumab. Regorafenib The metabolism of Regorafenib can be increased when combined with Bexarotene. Repaglinide The metabolism of Repaglinide can be decreased when combined with Bexarotene. Retapamulin The metabolism of Retapamulin can be increased when combined with Bexarotene. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Bexarotene. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Bexarotene. Ribociclib The metabolism of Bexarotene can be decreased when combined with Ribociclib. Rifampicin The metabolism of Bexarotene can be increased when combined with Rifampicin. Rifamycin The metabolism of Bexarotene can be increased when combined with Rifamycin. Rifapentine The metabolism of Bexarotene can be increased when combined with Rifapentine. Rilonacept The metabolism of Bexarotene can be increased when combined with Rilonacept. Rilpivirine The serum concentration of Rilpivirine can be decreased when it is combined with Bexarotene. Rimegepant The metabolism of Rimegepant can be increased when combined with Bexarotene. Riociguat The metabolism of Riociguat can be decreased when combined with Bexarotene. Risankizumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Risankizumab. Ritonavir The serum concentration of Bexarotene can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Bexarotene. Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Bexarotene. Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Bexarotene. Roflumilast Roflumilast may increase the immunosuppressive activities of Bexarotene. Rolapitant The metabolism of Rolapitant can be increased when combined with Bexarotene. Rolitetracycline The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Rolitetracycline. Romidepsin The metabolism of Romidepsin can be increased when combined with Bexarotene. Ropeginterferon The risk or severity of adverse effects can be increased when Bexarotene is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Ropivacaine. Rosiglitazone The metabolism of Rosiglitazone can be decreased when combined with Bexarotene. Rosuvastatin The metabolism of Rosuvastatin can be increased when combined with Bexarotene. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Bexarotene. Roxadustat The metabolism of Roxadustat can be decreased when combined with Bexarotene. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bexarotene. Rucaparib The metabolism of Bexarotene can be decreased when combined with Rucaparib. Rupatadine The metabolism of Rupatadine can be decreased when combined with Bexarotene. Ruxolitinib The metabolism of Ruxolitinib can be increased when combined with Bexarotene. Salicylic acid The metabolism of Salicylic acid can be decreased when combined with Bexarotene. Saquinavir The metabolism of Bexarotene can be decreased when combined with Saquinavir. Recycling The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Sarecycline. Sarilumab The risk or severity of adverse effects can be increased when Bexarotene is combined with Sarilumab. Satralizumab The serum concentration of Bexarotene can be decreased when it is combined with Satralizumab. Secukinumab The metabolism of Bexarotene can be increased when combined with Secukinumab. Segesterone acetate The metabolism of Segesterone acetate can be increased when combined with Bexarotene. Selegiline The metabolism of Selegiline can be decreased when combined with Bexarotene. Selexipag The metabolism of Selexipag can be decreased when combined with Bexarotene. Selpercatinib The serum concentration of Selpercatinib can be decreased when it is combined with Bexarotene. Selumetinib The serum concentration of Selumetinib can be decreased when it is combined with Bexarotene. Sertraline The metabolism of Bexarotene can be decreased when combined with Sertraline. Sildenafil The metabolism of Bexarotene can be decreased when combined with Sildenafil. Siltuximab The metabolism of Bexarotene can be increased when combined with Siltuximab. Simeprevir The metabolism of Bexarotene can be decreased when combined with Simeprevir. Simvastatin The metabolism of Simvastatin can be decreased when combined with Bexarotene. Siponimod The metabolism of Siponimod can be increased when combined with Bexarotene. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bexarotene. Sirolimus The metabolism of Sirolimus can be increased when combined with Bexarotene. Sitagliptin The metabolism of Sitagliptin can be decreased when combined with Bexarotene. Sitaxentan The metabolism of Bexarotene can be decreased when combined with Sitaxentan. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Bexarotene. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Bexarotene. Somatrogon The metabolism of Bexarotene can be increased when combined with Somatrogon. Sonidegib The metabolism of Sonidegib can be increased when combined with Bexarotene. Tioguanine The risk or severity of adverse effects can be increased when Bexarotene is combined with Tioguanine. Tipranavir The metabolism of Bexarotene can be decreased when combined with Tipranavir. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Bexarotene. Tivozanib The metabolism of Tivozanib can be increased when combined with Bexarotene. Tixocortol The risk or severity of adverse effects can be increased when Bexarotene is combined with Tixocortol. Tocilizumab The metabolism of Bexarotene can be increased when combined with Tocilizumab. Tofacitinib Bexarotene may increase the immunosuppressive activities of Tofacitinib. Tolazamide The metabolism of Tolazamide can be decreased when combined with Bexarotene. Tolbutamide The metabolism of Tolbutamide can be decreased when combined with Bexarotene. Tolterodine The metabolism of Tolterodine can be decreased when combined with Bexarotene. Tolvaptan The metabolism of Tolvaptan can be increased when combined with Bexarotene. Topotecan The risk or severity of adverse effects can be increased when Bexarotene is combined with Topotecan. Torasemide The metabolism of Torasemide can be decreased when combined with Bexarotene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Bexarotene. Trabectedin The metabolism of Trabectedin can be increased when combined with Bexarotene. Tramadol The metabolism of Tramadol can be increased when combined with Bexarotene. Tranylcypromine The metabolism of Bexarotene can be decreased when combined with Tranylcypromine. Trastuzumab Trastuzumab may increase the neutropenic activities of Bexarotene. Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be increased when combined with Bexarotene. Treprostinil The metabolism of Treprostinil can be decreased when combined with Bexarotene. Tretinoin The risk or severity of adverse effects can be increased when Bexarotene is combined with Tretinoin. Triamcinolone The risk or severity of adverse effects can be increased when Bexarotene is combined with Triamcinolone. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Bexarotene. Triclabendazole The metabolism of Bexarotene can be decreased when combined with Triclabendazole. Trifluridine The risk or severity of adverse effects can be increased when Bexarotene is combined with Trifluridine. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Bexarotene. Trilostane The risk or severity of adverse effects can be increased when Bexarotene is combined with Trilostane. Trimethadione The metabolism of Trimethadione can be decreased when combined with Bexarotene. Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Bexarotene. Trimipramine The metabolism of Trimipramine can be decreased when combined with Bexarotene. Troglitazone The metabolism of Bexarotene can be decreased when combined with Troglitazone. Troleandomycin The metabolism of Bexarotene can be decreased when combined with Troleandomycin. Tucatinib The metabolism of Tucatinib can be decreased when combined with Bexarotene. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Bexarotene. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Bexarotene. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Bexarotene. Ubrogepant The serum concentration of Ubrogepant can be decreased when it is combined with Bexarotene. Ulipristal The metabolism of Ulipristal can be increased when combined with Bexarotene. Upadacitinib The risk or severity of adverse effects can be increased when Bexarotene is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Bexarotene. Valdecoxib The metabolism of Bexarotene can be decreased when combined with Valdecoxib. Valproic acid Valproic acid may increase the Pseudotumor Cerebri activities of Bexarotene. Valsartan The metabolism of Bexarotene can be decreased when combined with Valsartan. Vandetanib The metabolism of Vandetanib can be increased when combined with Bexarotene. Pregnancy and Lactation US FDA pregnancy category: Not Assigned Pregnancy The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out. Lactation Breastfeeding should be discontinued during treatment. Excreted into human milk: Unknown Excreted into animal milk: Data not available How should this medicine be used?

Bexarotene comes as a capsule to take by mouth. It is usually taken once a day with food. Take bexarotene at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take bexarotene exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the capsules whole; do not chew the…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)